ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1161

IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis

Marie-Christin Hoffmann1, Natalie Fadle1, Evi Regitz1, Klaus-Dieter Preuss1, Marina Zaks2, Elisabeth Stöger3, Vincent Zimmer4, Philipp Klemm5, Gunter Assmann6, Bernhard Thurner7, Claudia Pföhler8, Joerg Thomas Bittenbring1, Christoph Kessel9 and Lorenz Thurner1, 1José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany, 2Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany, 3Evangelische Kliniken Essen-Mitte gGmbH, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany, Essen, Germany, 4Department of Medicine, Knappschaftsklinikum Saar, Püttlingen, Germany, Department of Medicine II, Saarland University Medical School, Homburg/Saar, Germany, 5Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, 6Klinik für Rheumatologie und klinische Immunologie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany, Minden, Germany, 7Department of Pediatrics, Klinikum Kempten, Kempten, Germany, 8Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany, 9Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany, Münster, Germany

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), autoimmune diseases, Interleukins, Psoriatic arthritis, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Basic Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Psoriasis arthritis is known as a subtype of seronegative spondylarthritis. However, autoantibodies against the receptor antagonist at tumor necrosis factor receptor 1 and 2 (TNFR1&2) and death receptor 3 (DR3) Progranulin (PGRN) have been described in psoriatic arthritis.Recently, neutralizing autoantibodies against the interleukin-1 receptor antagonist (IL-1Ra) have been described in severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-related diseases, considered to create a pro-inflammatory environment. The interleukin-36 (IL-36) cytokine family is mainly expressed in the skin and, thus, might contribute to the pathogenesis of psoriasis (Ps) and psoriatic arthritis (PsA). In the present study, we screened for hypothetic autoantibodies against the anti-inflammatory mediators IL-36-receptor antagonist (IL-36Ra) and anti-inflammatory IL-38 in PsA, Ps and controls.

Methods: Sera were screened by ELISA for antibodies against IL-36Ra and IL-38. Serum samples of patients with PsA (n=254), Ps (n=102), systemic lupus erythematosus (SLE, n=50), rheumatic arthritis (RA, n=100), ulcerative colitis (UC, n=50), Crohn´s disease (CD, n=50), and healthy controls (HC, n=49) were analyzed. Western blot analysis and isoelectric focusing was performed to detect possible atypical IL-36Ra isoforms. Native western blot was done to detect free IL-36-Ra and possible immunocomplexed IL-36Ra. IL-36Ra serum levels were determined by ELISA.

Results: Anti-IL-36Ra antibodies (Abs) were detected in 5 of 102 (4.9%) patients with Ps, in 12 of 254 (4.7%) patients with PsA and in 1 of 50 (2%) patients with CD. There was no detection of anti-IL-36Ra-antibodies in RA individuals. No anti-IL-38-antibodies could be detected. The antibodies against IL-36Ra belonged to IgG subclass 1, and their titers ranged between 1:200 to 1:1.600. No atypically post-translationally modified isoforms of IL-36Ra have been detected in seropositive patients. The native western blot showed that sera with anti-IL-36Ra-antibodies had less strong bands for free IL-36Ra, but additional bands for IgG-immunocomplexed IL-36Ra. In contrast, seronegative serum samples showed only a band for free IL-36Ra. The concentration of IL-36Ra determined by ELISA was significantly reduced in samples of IL-36Ra-Ab seropositive patients.

Conclusion: Apart from anti-PGRN and anti-IL-1Ra Abs, Abs against IL-36Ra represent a further member of the class of autoantibodies neutralizing anti-inflammatory receptor antagonists. They were found in small subsets of patients with Ps and PsA, where IL-36 imbalances are known for their pathophysiologic impact. Beside PGRN-Abs this is a second proinflammatory autoantibody in PsA.

Supporting image 1

Occurrence of anti-IL_36Ra-antibodies

Supporting image 2

Anti-IL_36Ra antibody subclasses

Supporting image 3

Titers of anti-IL_36Ra antibodies


Disclosures: M. Hoffmann, None; N. Fadle, None; E. Regitz, None; K. Preuss, None; M. Zaks, None; E. Stöger, None; V. Zimmer, None; P. Klemm, None; G. Assmann, None; B. Thurner, Nutricia Milupa, BioNTech; C. Pföhler, None; J. Bittenbring, None; C. Kessel, Novartis, Swedish Orphan Biovitrum (SOBI), Novartis; L. Thurner, Wilhelm Sander-Stiftung, BioNanoMed, Homburger Forschungsförderung programme of the University of Saarland, AbbVie, Janssen, EUSA-Pharm, Takeda, AstraZeneca, Merck, EUSA Pharma.

To cite this abstract in AMA style:

Hoffmann M, Fadle N, Regitz E, Preuss K, Zaks M, Stöger E, Zimmer V, Klemm P, Assmann G, Thurner B, Pföhler C, Bittenbring J, Kessel C, Thurner L. IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/il-36-receptor-antagonist-antibodies-in-psoriasis-and-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-36-receptor-antagonist-antibodies-in-psoriasis-and-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology